Benzyl-methyl-octadecylazanium;chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzyl-methyl-octadecylazanium;chloride
• 英文别名: benzyl-methyl-octadecylazanium;chloride
• 化学式: C26H48ClN
• 分子量: 410.1
• InChiKey: ACINEQKBTSRMIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.8
• 重原子数：
  28
• 可旋转键数：
  19
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  3.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• NEW PROCESS FOR PREPARATION OF ATOVAQUONE AND NOVEL INTERMEDIATES THEREOF
  申请人：Kumar Ashok

  公开号：US20100081847A1

  公开（公告）日：2010-04-01

  Disclosed herein is a novel process for preparation of atovaquone. The process includes reacting 1,4-naphthoquinone with trans-4-(4-chlorophenyl) cyclohexane carboxylic acid followed by halogenation to obtain a dihalo-compound. Further, dehydrohalogenation of the dihalo-compound produces a monohalogeno-compound which under goes hydrolysis to produce atovaquone. The invention also discloses atovaquone in a substantially pure and well defined polymorphic form designated as “Form IPCA-ATO,” and the preparation thereof.

  本文披露了一种用于制备阿托伐醌的新型工艺。该工艺包括将1,4-萘醌与反式-4-(4-氯苯基)环己烷羧酸反应，然后进行卤化以获得二卤化合物。此外，二卤化合物的脱卤化产生单卤化合物，经水解生成阿托伐醌。该发明还披露了一种名为“Form IPCA-ATO”的高度纯净和明确定义的多晶形态的阿托伐醌，以及其制备方法。
• Highly Pure Paliperidone or a Pharmaceutically Acceptable Salt Thereof Substantially Free of Keto Impurity
  申请人：Bapat Uday Rajaram

  公开号：US20090247553A1

  公开（公告）日：2009-10-01

  Provided herein is a highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-7,8-dihydro-6H-pyrido[1,2-a]pyrimidin-4,9-dione, a process for the preparation thereof, and pharmaceutical compositions comprising highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity.

  本文提供了一种高纯度的帕利哌酮或其在很大程度上不含酮杂质的药用盐，化学名称为3-[2-[4-(6-氟-1,2-苯并异噁唑-3-基)-1-哌啶基]乙基]-2-甲基-7,8-二氢-6H-吡啶并[1,2-a]嘧啶-4,9-二酮，以及其制备方法和包含高纯度帕利哌酮或其在很大程度上不含酮杂质的药用盐的药物组合物。
• SOLID STATE FORMS OF PALIPERIDONE SALTS AND PROCESS FOR THE PREPARATION THEREOF
  申请人：Dixit Girish

  公开号：US20120100188A1

  公开（公告）日：2012-04-26

  Provided herein are solid state forms of paliperidone salts, processes for preparation, pharmaceutical compositions, and method of treating thereof. Paliperidone is represented by the following structural formula (I): More particularly, provided are solid state forms of paliperidone acid addition salts, wherein the acid counter ion is provided by an acid selected from the group consisting of L-(+)-tartaric acid, p-toluenesulfonic acid, maleic acid, oxalic acid, fumaric acid, acetic acid and malic acid. Provided also herein is a process for preparing substantially pure paliperidone free base using the solid state forms of paliperidone salts.

  本文提供了帕利哌酮盐的固态形式，制备方法，药物组合物以及治疗方法。帕利哌酮的结构式如下（I）：更具体地，提供了帕利哌酮酸加合物盐的固态形式，其中酸对离子由L-(+)-酒石酸、对甲苯磺酸、马来酸、草酸、富马酸、乙酸和苹果酸等酸中选择提供。本文还提供了一种利用帕利哌酮盐的固态形式制备基本纯净的帕利哌酮游离碱的方法。
• PROCESSES FOR PREPARING TICAGRELOR INTERMEDIATE, 4,6-DICHLORO-5-NITRO-2-(PROPYLTHIO)PYRIMIDINE
  申请人：Khile Anil Shahaji

  公开号：US20130030176A1

  公开（公告）日：2013-01-31

  Provided herein are improved, commercially viable and industrially advantageous processes for the preparation of a substantially pure ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine, Formula (II). The intermediate is useful for preparing ticagrelor, or a pharmaceutically acceptable salt thereof in high yield and purity.

  本文提供了一种改进的、商业可行的和在工业上具有优势的工艺，用于制备一种基本纯的替卡格雷中间体4,6-二氯-5-硝基-2-(丙硫基)嘧啶，化学式（II）。该中间体可用于高产率和高纯度制备替卡格雷或其药用可接受的盐。
• [EN] SOLID STATE FORMS OF PALIPERIDONE SALTS AND PROCESS FOR THE PREPARATION THEREOF<br/>[FR] FORMES À L'ÉTAT SOLIDE DE SELS DE PALIPÉRIDONE ET LEUR PROCÉDÉ DE PRÉPARATION
  申请人：ACTAVIS GROUP PTC EHF

  公开号：WO2010136895A1

  公开（公告）日：2010-12-02

  Provided herein are solid state forms of paliperidone salts, processes for preparation, pharmaceutical compositions, and method of treating thereof. Paliperidone is represented by the following structural formula (I) : More particularly, provided are solid state forms of paliperidone acid addition salts, wherein the acid counter ion is provided by an acid selected from the group consisting of L- (+) -tartaric acid, p- toluenesulfonic acid, maleic acid, oxalic acid, fumaric acid, acetic acid and malic acid. Provided also herein is a process for preparing substantially pure paliperidone free base using the solid state forms of paliperidone salts.

  本文提供了帕利哌酮盐的固态形式，制备方法，药物组合物和治疗方法。帕利哌酮的结构式如下（I）：更具体地，提供了帕利哌酮酸加合物盐的固态形式，其中酸对离子由选自L-（+）-酒石酸、对甲苯磺酸、马来酸、草酸、富马酸、乙酸和苹果酸的酸所提供。此外，还提供了一种利用帕利哌酮盐的固态形式制备基本纯帕利哌酮游离基的方法。